🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆
Updated 12 Aug 2026 · EMA CTIS official data

Clinical Trials in Portugal

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

36
Recent authorisations
26
Phase III trials
Portugal
Selected country
Phase III Skin and Connective Tissue Diseases Authorised 03/08/2026
A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)
Systemic sclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 141 participants
📍 Denmark · Sweden · Netherlands · Germany · Belgium · France · Greece · Norway · Finland · Czechia · Portugal · Bulgaria · Spain · Austria · Estonia · Italy · Lithuania
2025-523884-39-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026
A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease
Moderately to Severely Active Crohn’s Disease
Janssen Cilag International · 194 participants
📍 Norway · Romania · Austria · Italy · Slovakia · Germany · Hungary · Netherlands · Belgium · France · Portugal · Czechia · Poland · Spain · Greece
2026-525922-39-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026
A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International · 302 participants
📍 France · Bulgaria · Romania · Slovakia · Norway · Denmark · Greece · Italy · Austria · Poland · Netherlands · Czechia · Germany · Belgium · Spain · Hungary · Portugal
2026-525923-26-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/07/2026
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3
Spinocerebellar ataxia type 3
Institut De Recherches Internationales Servier IRIS · 50 participants
📍 France · Denmark · Spain · Portugal
2025-525111-17-00 on CTIS ↗
Phase I Neoplasms Authorised 27/07/2026
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer
Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG · 44 participants
📍 Portugal · Denmark · Spain · France
2025-522209-40-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026
A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes
Participants with obesity with or without type 2 diabetes
Novo Nordisk A/S · 1140 participants
📍 Greece · Portugal · France · Slovakia · Bulgaria · Netherlands · Romania · Italy · Austria · Poland · Hungary · Spain · Czechia · Belgium
2025-522488-14-00 on CTIS ↗
Phase III Hormonal diseases Authorised 23/07/2026
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
Classic Congenital Adrenal Hyperplasia (CAH)
Neurocrine Biosciences Inc. · 71 participants
📍 Czechia · Germany · Sweden · Portugal · Romania · Bulgaria · Italy · Austria · Spain
2025-524282-24-00 on CTIS ↗
Phase III Digestive System Diseases Authorised 21/07/2026
A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis
Ipsen Bioscience Inc. · 127 participants
📍 Spain · Sweden · Germany · Romania · Finland · Portugal · Austria · Italy · Denmark · Czechia · France · Netherlands · Poland · Belgium · Norway
2026-525242-29-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 20/07/2026
A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity
Participants with overweight or obesity
Novo Nordisk A/S · 171 participants
📍 Sweden · Greece · Hungary · Portugal
2025-524249-29-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/07/2026
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease
Huntington’s Disease
Novartis Pharma AG · 368 participants
📍 Norway · Poland · Spain · Sweden · Bulgaria · Netherlands · Finland · Portugal · Austria · Italy · Greece · Ireland · Czechia · France · Romania · Belgium · Germany · Denmark · Slovakia · Hungary
2025-522227-99-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 14/07/2026
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS)
Apellis Pharmaceuticals Inc. · 97 participants
📍 France · Portugal · Spain · Slovakia · Italy · Germany · Poland
2025-524448-36-00 on CTIS ↗
Phase I/II Neoplasms Authorised 13/07/2026
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma
Multiple Myeloma (MM), Multiple Myeloma (MM)
AbbVie Deutschland GmbH & Co. KG · 88 participants
📍 Germany · Poland · Czechia · Belgium · France · Greece · Sweden · Portugal · Italy
2025-525105-20-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 07/07/2026
A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)
Fibrosing interstitial lung disease
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 20 participants
📍 Belgium · Greece · Germany · France · Finland · Spain · Czechia · Poland · Italy · Netherlands · Denmark · Portugal
2025-523369-32-00 on CTIS ↗
Phase III Neoplasms Authorised 06/07/2026
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
Metastatic Pancreatic Ductal Adenocarcinoma; PDAC
AbbVie Deutschland GmbH & Co. KG · 194 participants
📍 Portugal · Spain · France · Italy · Germany · Austria
2025-522563-15-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype
Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement · 613 participants
📍 Denmark · Sweden · Poland · Estonia · Portugal · Latvia · Spain · Hungary · Germany · Finland · Italy · Belgium · France
2024-518016-39-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 30/06/2026
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Pulmonary Hypertension Associated with Interstitial Lung Disease
Insmed Inc. · 165 participants
📍 Greece · France · Italy · Belgium · Denmark · Germany · Poland · Czechia · Portugal · Austria · Spain · Romania
2025-521769-29-00 on CTIS ↗
Phase I/II Nervous System Diseases Authorised 30/06/2026
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome
Dravet Syndrome
Ionis Pharmaceuticals Inc. · 12 participants
📍 Spain · France · Belgium · Portugal · Germany
2025-523835-20-00 on CTIS ↗
Phase III Neoplasms Authorised 29/06/2026
AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer
Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG · 243 participants
📍 Greece · Portugal · Germany · Belgium · Spain
2025-521712-19-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC · 467 participants
📍 Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 17/06/2026
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
Bristol-Myers Squibb Services Unlimited Company · 318 participants
📍 Finland · Portugal · Hungary · Ireland · Poland · Greece · France · Belgium · Denmark · Italy · Spain · Netherlands · Austria · Germany
2025-522373-10-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 10/06/2026
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Eli Lilly & Co. · 104 participants
📍 Latvia · Portugal · Greece · France · Czechia · Italy · Poland · Slovakia · Hungary · Croatia · Lithuania
2025-524404-29-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 08/06/2026
A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)
Moderate Calcific Aortic Valve Stenosis (CAVS)
Kardigan Inc. · 496 participants
📍 Norway · Czechia · Portugal · Austria · Poland · France · Spain
2025-522176-86-01 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 08/06/2026
A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease
Congenital Heart Disease
Chiesi Farmaceutici S.p.A. · 48 participants
📍 Netherlands · Germany · Portugal · Austria
2025-523109-14-00 on CTIS ↗
Phase III Eye Diseases Authorised 05/06/2026
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited · 250 participants
📍 Austria · Slovakia · Portugal · Czechia · Hungary · Spain · France · Denmark · Italy · Croatia
2025-524894-17-00 on CTIS ↗
Phase II Congenital, Hereditary, and Neonatal Diseases and Abnormalities Authorised 29/05/2026
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
Cystic fibrosis
Vertex Pharmaceuticals Inc. · 80 participants
📍 Spain · Sweden · Germany · Italy · Belgium · Czechia · Ireland · Portugal · Netherlands · France · Denmark
2025-523400-72-00 on CTIS ↗
Phase II Mental Disorders Authorised 27/05/2026
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Maplight Therapeutics Inc. · 85 participants
📍 Italy · Poland · Czechia · Portugal · Bulgaria · France · Slovakia · Romania · Hungary
2025-521757-16-00 on CTIS ↗
Phase IV Female Urogenital Diseases and Pregnancy Complications Authorised 22/05/2026
Exogenous progesterone as ovulation trigger – a pilot study
Infertility
Instituto Valenciano De Infertilidade Clinica De Reproducao Assistida Lda. · 10 participants
📍 Portugal
2025-523850-15-00 on CTIS ↗
Phase III Immune System Diseases Authorised 20/05/2026
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
Hidradenitis Suppurativa (HS)
Novartis Pharma AG · 307 participants
📍 Portugal · Greece · Germany · Hungary · France · Spain · Bulgaria · Slovakia · Poland · Czechia · Belgium · Italy
2025-523259-72-00 on CTIS ↗
Phase III Neoplasms Authorised 19/05/2026
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
Metastatic hormone-sensitive prostate cancer
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard · 292 participants
📍 Spain · Germany · France · Portugal · Italy
2025-524408-30-01 on CTIS ↗
Phase III Hemic and Lymphatic Diseases Authorised 19/05/2026
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding
VarmX B.V. · 443 participants
📍 Belgium · Germany · Italy · France · Czechia · Bulgaria · Hungary · Spain · Netherlands · Poland · Austria · Estonia · Romania · Portugal · Lithuania
2025-521632-12-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 19/05/2026
PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases
Proteinuric kidney diseases
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A. · 66 participants
📍 Portugal · Greece · Italy · Poland · Estonia · Slovakia · Sweden · Denmark · Belgium · Norway · Romania · France · Spain · Germany · Netherlands · Croatia
2025-523425-17-00 on CTIS ↗
Phase III Bacterial Infections and Mycoses Authorised 19/05/2026
Multicentre, randomised, double-blind, placebo-controlled clinical trial to confirm the efficacy, safety, and clinical impact of the mucosal bacterial therapeutic vaccine MV140 in women with non-complicated recurrent urinary tract infections (rUTIs).
Recurrent Non-Complicated Urinary Tract Infections (rUTIs).
Inmunotek S.L. · 252 participants
📍 Portugal
2025-524377-16-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 18/05/2026
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS)
Zenas Biopharma (USA) LLC · 398 participants
📍 Italy · Finland · Bulgaria · Greece · Belgium · Estonia · Portugal · Spain · Germany · France · Czechia · Slovakia · Romania · Croatia · Poland · Austria · Netherlands · Denmark · Sweden · Hungary
2025-524316-11-00 on CTIS ↗
Phase III Neoplasms Authorised 15/05/2026
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
Non-Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company · 265 participants
📍 Portugal · Norway · Sweden · Bulgaria · France · Belgium · Austria · Germany · Finland · Poland · Romania · Netherlands · Spain · Italy · Hungary · Czechia
2025-523586-18-00 on CTIS ↗
Phase I/II Neoplasms Authorised 15/05/2026
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
Advanced Solid Tumors
Eikon Therapeutics Inc. · 63 participants
📍 France · Spain · Norway · Italy · Germany · Austria · Poland · Finland · Portugal
2026-525248-13-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 15/05/2026
Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)
Participants with overweight or obesity, and type 2 diabetes
Novo Nordisk A/S · 440 participants
📍 Germany · Croatia · Portugal · Hungary · Bulgaria · Romania · Poland
2024-520446-31-00 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/portugal (Accessed: 13 August 2026).

Embed this data ↗

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker. See who's running these trials in our Company Directory, or compare pay across these markets in the EU Salary Guide.